Palvella stockholders approve 750K-share increase to 2024 equity plan; re-elect three directors

Proposal 3 - Approval, on an advisory basis, of the compensation of the Company’s named executive officers in 2025. The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers in 2025, as follows: Votes For Votes Against Abstentions Broker Non-Votes 10,008,180 160,717 7,157 1,401,415

Proposal 6 – Approval of an adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve Proposal 5. The stockholders approved an adjournment of the Annual Meeting to the extent there were insufficient votes to approve Proposal 5, but such an adjournment was not necessary in light of the approval of Proposal 5 at the Annual Meeting. The voting results for the adjournment proposal were as follows: Votes For Votes Against Abstentions Broker Non-Votes 7,649,243 2,519,068 7,743 1,401,415

Proposal 5 – Approval of an amendment to the Palvella Therapeutics, Inc. 2024 Equity Incentive Plan to increase the authorized shares issuable thereunder by 750,000 shares. The stockholders approved the Plan Amendment, as follows: Votes For Votes Against Abstentions Broker Non-Votes 7,692,709 2,475,470 7,875 1,401,415

Proposal 2 - Ratification of Independent Registered Public Accountant. The appointment of Ernst &Young LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year was ratified, as follows: Votes For Votes Against Abstentions 11,557,687 13,216 6,566

Proposal 4 - Approval, on an advisory basis, of the preferred frequency of future advisory votes on the compensation paid to the Company’s named executive officers. The stockholders approved, on an advisory basis, the preferred frequency of future advisory votes on compensation of the Company’s named executive officers, as follows: Every Year Every 2 Years Every 3 Years Abstain Broker Non-Votes 9,183,170 1,002 984,332 7,550 1,401,415

Proposal 1 - Election of Class III Directors. George M. Jenkins, Todd C. Davis and John Doux, M.D . were elected to the Board as Class III directors to serve until the Company’s 2029 Annual Meeting of Stockholders and until their successors, if any, are duly elected and qualified or appointed, or their earlier death, resignation, retirement, disqualification or removal, as follows: Name Votes For Votes Withheld Broker Non-Votes George M. Jenkins 9,907,220 268,834 1,401,415 Todd C. Davis 8,321,303 1,854,751 1,401,415 John Doux, M.D. 9,958,528 217,526 1,401,415